Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.93.

Several equities analysts have issued reports on ROIV shares. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America upped their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research report on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the sale, the executive now owns 18,836,547 shares of the company's stock, valued at approximately $226,038,564. The trade was a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares in the company, valued at $6,865,863. The trade was a 14.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,942,629 shares of company stock worth $23,071,486. 7.90% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Roivant Sciences by 27.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,287 shares of the company's stock valued at $838,000 after acquiring an additional 17,248 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in Roivant Sciences during the second quarter worth about $218,000. nVerses Capital LLC purchased a new stake in Roivant Sciences during the second quarter worth about $34,000. Natixis Advisors LLC grew its position in Roivant Sciences by 12.1% during the second quarter. Natixis Advisors LLC now owns 141,991 shares of the company's stock worth $1,500,000 after buying an additional 15,280 shares during the period. Finally, Arizona State Retirement System increased its holdings in Roivant Sciences by 31.5% in the second quarter. Arizona State Retirement System now owns 101,661 shares of the company's stock valued at $1,075,000 after buying an additional 24,333 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV traded down $0.39 during trading on Friday, hitting $11.69. 3,362,411 shares of the company were exchanged, compared to its average volume of 4,080,205. The firm's 50 day moving average price is $11.92 and its 200-day moving average price is $11.56. The stock has a market capitalization of $8.51 billion, a P/E ratio of 2.07 and a beta of 1.25. Roivant Sciences has a 12-month low of $9.69 and a 12-month high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.